Latest Information Update: 07 Jun 2001
At a glance
- Originator Unknown
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Hypersensitivity
Most Recent Events
- 15 Mar 2016 Biomarkers information updated
- 07 Jun 2001 Discontinued-II for Allergy in Japan (PO)